All In Biotech

Drug Trial Radar · NCT06396429

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 567 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

567

Actual

Start

May 13, 2024

Primary completion

Jul 7, 2025

Study completion Jul 7, 2025

Sponsor

Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

Conditions

  • Overweight or Obesity

Interventions

  • HRS9531 injectionDrug

    HRS9531 injection; low dose

  • HRS9531 injectionDrug

    HRS9531 injection; medium dose

  • HRS9531 injectionDrug

    HRS9531 injection, high dose

  • PlaceboDrug

    blank preparation, participants received matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in weight after 48 weeks of treatmentTime frame: Baseline, Week 48
  2. Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatmentTime frame: Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.